CADASIL Clinical Trial
Official title:
The Silent Cortical Infarcts in the Cerebral Amyloid Angiopathy: Is There a Link With Subarachnoid Hemorrhage?
The Cerebral Amyloid angiopathy (CAA) is the leading cause of cortical hemorrhage after 65 years. The presence of cerebral infarction is also reported anatomically in the AAC. MRI studies of these infarcts are rare. They are described as punctate, cortical silent. Frequency and pathophysiology is poorly understood. The investigators put the question of a link with hemorrhagic lesions of the AAC.
Main objective / secondary
The objectives are:
- To assess frequency of cortical infarcts in the cohort of patients recruited
consecutively likely AAFC GHPSJ since 2007
- To assess the link between the presence of myocardial infarction and the clinical
characteristics of patients and
- To study the relationship between topography and the brain hemorrhage one hand,
meningeal hemorrhage other.
Inclusion / exclusion Any patient who was diagnosed as carrying a probable AAC according to
the Boston criteria and has had a brain MRI with the following sequences: classic or
enhanced diffusion (or DTI B2000), T1, T2 FLAIR, T2EG (T2 * or SWAN)
Methodology This is a non-interventional study single center, including AAC patients
hospitalized in the Hospital Group Paris Saint-Joseph from May 2007 to May 2014.
Clinical patient characteristics were collected from their medical records. Patients are
aware of the potential use of their data for medical research by information contained in
the handbook of the institution.
Brain MRI will be proofread by a neurologist and a neuroradiologist to clarify:
- the number and location of myocardial puncture
- the number and location of macro-bleeding
- the number of microbleeds (micro-bleeding)
- the presence and location of subarachnoid hemorrhage and / or hemosiderosis
- the location of the puncture infarction compared to macro-hemorrhage and subarachnoid
hemorrhage / hemosiderosis: ipsilateral <5cm, ipsilateral> 5cm, another location The
clinical data and MRI will be entered on a file, with data anonymisation. Statistical
analysis will be done by a neurologist service.
Number of topics:
- It is estimated that enrollment of patients with AAC by the UNV GHPSJ is approximately
10 patients per year. The number of screened patients during the study period should be
about 70.
- Taking into account those whose MRI will be judged of insufficient quality (excluded),
the number of patients included in the analysis should be around 50.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT03724136 -
Alzheimer's Autism and Cognitive Impairment Stem Cell Treatment Study
|
N/A | |
Recruiting |
NCT05755997 -
CERebrolysin In CADASIL
|
Phase 2 | |
Recruiting |
NCT06148051 -
AusCADASIL: An Australian Cohort of CADASIL
|
||
Recruiting |
NCT04310098 -
CADASIL Registry Study
|
||
Completed |
NCT01114815 -
Research Study on Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL)
|
N/A | |
Recruiting |
NCT05677880 -
Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL) Study
|
||
Recruiting |
NCT02795052 -
Neurologic Stem Cell Treatment Study
|
N/A | |
Recruiting |
NCT01361763 -
Safety Study of Dabigatran in CADASIL
|
Phase 2 | |
Completed |
NCT02071784 -
Imaging Study of Neurovascular Coupling in Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL)
|
||
Completed |
NCT06072118 -
Adrenomedullin for CADASIL
|
Phase 2 | |
Active, not recruiting |
NCT02699190 -
LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies
|
||
Recruiting |
NCT05473637 -
Taiwan Associated Genetic and Nongenetic Small Vessel Disease
|
||
Enrolling by invitation |
NCT02032225 -
Generation of a Cellular Model of CADASIL From Skin Fibroblasts
|
N/A | |
Recruiting |
NCT03047369 -
The Myelin Disorders Biorepository Project
|
||
Active, not recruiting |
NCT04658823 -
Efficacy and Safety of Tocotrienols in CADASIL
|
Phase 2 | |
Withdrawn |
NCT04334408 -
Safety and Efficacy of Fremanezumab for Migraine in Adult CADASIL
|
Phase 2 | |
Recruiting |
NCT05734378 -
Prognosis of Cerebral Small Vessel Disease
|
||
Recruiting |
NCT05491980 -
Florida Cerebrovascular Disease Biorepository and Genomics Center
|
||
Recruiting |
NCT04036084 -
Development of New Biomarkers With Magnetic Resonance Imaging for Longitudinal Studies in CADASIL Angiopathy
|
||
Completed |
NCT01865604 -
Impact of tDCS on Cerebral Autoregulation
|
N/A |